Cargando…

Rapid Onset Severe Immune Thrombocytopenia following mRNA COVID-19 Vaccine in a Young Patient

The coronavirus disease 2019 (COVID-19) pandemic has affected millions of people around the world. Vaccination against COVID-19 has been approved for the following three vaccines in the United States: Pfizer-BioNTech, Moderna, and Janssen. Hematological complications of vaccination have been reporte...

Descripción completa

Detalles Bibliográficos
Autores principales: Avila, Jorge, Degirmenci, Huseyin Berk, Contreras Chavez, Pamela, Battinelli, Elisabeth M., Fleisher, Jorge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027455/
https://www.ncbi.nlm.nih.gov/pubmed/36950529
http://dx.doi.org/10.1155/2023/7877536
_version_ 1784909713007181824
author Avila, Jorge
Degirmenci, Huseyin Berk
Contreras Chavez, Pamela
Battinelli, Elisabeth M.
Fleisher, Jorge
author_facet Avila, Jorge
Degirmenci, Huseyin Berk
Contreras Chavez, Pamela
Battinelli, Elisabeth M.
Fleisher, Jorge
author_sort Avila, Jorge
collection PubMed
description The coronavirus disease 2019 (COVID-19) pandemic has affected millions of people around the world. Vaccination against COVID-19 has been approved for the following three vaccines in the United States: Pfizer-BioNTech, Moderna, and Janssen. Hematological complications of vaccination have been reported in the literature but remain as a rare phenomenon. We present the case of a patient who developed severe thrombocytopenia within twenty-four hours following the Pfizer-BioNTech vaccination. Commonly encountered differentials including heparin-induced thrombocytopenia and common viral etiologies were ruled out, and other causes such as drug reactions deemed unlikely as the etiology of this presentation after a broad workup. Nucleocapsid antibodies against COVID-19 were found to be positive which indicated that vaccination was at least the second encounter with this virus for our patient, which has been reported previously as the cause of immune thrombocytopenia (ITP), and this might be the culprit for sudden onset. He responded to the first-line ITP treatment with corticosteroids and intravenous immunoglobulin (IVIG) as evidenced by the fast recovery of platelet count and lack of recurrence of thrombocytopenia.
format Online
Article
Text
id pubmed-10027455
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-100274552023-03-21 Rapid Onset Severe Immune Thrombocytopenia following mRNA COVID-19 Vaccine in a Young Patient Avila, Jorge Degirmenci, Huseyin Berk Contreras Chavez, Pamela Battinelli, Elisabeth M. Fleisher, Jorge Case Rep Hematol Case Report The coronavirus disease 2019 (COVID-19) pandemic has affected millions of people around the world. Vaccination against COVID-19 has been approved for the following three vaccines in the United States: Pfizer-BioNTech, Moderna, and Janssen. Hematological complications of vaccination have been reported in the literature but remain as a rare phenomenon. We present the case of a patient who developed severe thrombocytopenia within twenty-four hours following the Pfizer-BioNTech vaccination. Commonly encountered differentials including heparin-induced thrombocytopenia and common viral etiologies were ruled out, and other causes such as drug reactions deemed unlikely as the etiology of this presentation after a broad workup. Nucleocapsid antibodies against COVID-19 were found to be positive which indicated that vaccination was at least the second encounter with this virus for our patient, which has been reported previously as the cause of immune thrombocytopenia (ITP), and this might be the culprit for sudden onset. He responded to the first-line ITP treatment with corticosteroids and intravenous immunoglobulin (IVIG) as evidenced by the fast recovery of platelet count and lack of recurrence of thrombocytopenia. Hindawi 2023-03-13 /pmc/articles/PMC10027455/ /pubmed/36950529 http://dx.doi.org/10.1155/2023/7877536 Text en Copyright © 2023 Jorge Avila et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Avila, Jorge
Degirmenci, Huseyin Berk
Contreras Chavez, Pamela
Battinelli, Elisabeth M.
Fleisher, Jorge
Rapid Onset Severe Immune Thrombocytopenia following mRNA COVID-19 Vaccine in a Young Patient
title Rapid Onset Severe Immune Thrombocytopenia following mRNA COVID-19 Vaccine in a Young Patient
title_full Rapid Onset Severe Immune Thrombocytopenia following mRNA COVID-19 Vaccine in a Young Patient
title_fullStr Rapid Onset Severe Immune Thrombocytopenia following mRNA COVID-19 Vaccine in a Young Patient
title_full_unstemmed Rapid Onset Severe Immune Thrombocytopenia following mRNA COVID-19 Vaccine in a Young Patient
title_short Rapid Onset Severe Immune Thrombocytopenia following mRNA COVID-19 Vaccine in a Young Patient
title_sort rapid onset severe immune thrombocytopenia following mrna covid-19 vaccine in a young patient
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027455/
https://www.ncbi.nlm.nih.gov/pubmed/36950529
http://dx.doi.org/10.1155/2023/7877536
work_keys_str_mv AT avilajorge rapidonsetsevereimmunethrombocytopeniafollowingmrnacovid19vaccineinayoungpatient
AT degirmencihuseyinberk rapidonsetsevereimmunethrombocytopeniafollowingmrnacovid19vaccineinayoungpatient
AT contreraschavezpamela rapidonsetsevereimmunethrombocytopeniafollowingmrnacovid19vaccineinayoungpatient
AT battinellielisabethm rapidonsetsevereimmunethrombocytopeniafollowingmrnacovid19vaccineinayoungpatient
AT fleisherjorge rapidonsetsevereimmunethrombocytopeniafollowingmrnacovid19vaccineinayoungpatient